Close Menu
    Facebook X (Twitter) Instagram
    Qatar OutlookQatar Outlook
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Qatar OutlookQatar Outlook
    Home » Daewoong Pharmaceutical Announce Publication of Phase 3 Study of ‘Envlo’, a New Treatment for Diabetes, in the International SCIE Journal
    PR Newswire

    Daewoong Pharmaceutical Announce Publication of Phase 3 Study of ‘Envlo’, a New Treatment for Diabetes, in the International SCIE Journal

    April 24, 2023
    Share
    Facebook Twitter LinkedIn Pinterest Email

    SEOUL, South Korea, April 24, 2023 /PRNewswire/ — The research results of Daewoong Pharmaceutical’s SGLT-2 inhibitor new drug, ‘Envlo’, have been internationally acknowledged.

    On April 4, Daewoong Pharmaceutical (CEO Seng-ho Jeon and Chang-jae Lee) announced that the efficacy and safety evaluation study of monotherapy of the 36th novel drug from South Korea, Envlo (ingredient name: Enavogliflozin) (ENHANCE-A), has been published in the international SCIE journal, ‘Diabetes, Obesity and Metabolism, DOM.’

    The title of the paper is ‘Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial.’

    According to the study, the efficacy endpoint ‘change of glycated hemoglobin (HbA1c) level at Week 24 after administration of Envlo’ showed -0.88%p for Envlo group and 0.11%p for placebo group, and a significant difference between the two groups showed -0.99%p, proving the superiority of Envlo compared to placebo. Also, no significant differences were found in the incidence of adverse events, adverse drug reaction, and serious adverse events between the two groups.

    It was statistically significant (p<0.0001) that the proportion of subjects achieving a therapeutic glycemic response (HbA1c < 7% or < 6.5%), indicating the potential as an effective diabetes treatment. Moreover, there was evidence of indirect improvement effects, such as insulin resistance (HOMA-IR) and obesity-related indicators.

    Meanwhile, Daewoong Pharmaceutical also released a paper on the phase 3 study of the combination therapy of Envlo with metformin (ENHANCE-M) and metformin & gemigliptin (ENHANCE-D).

    The ENHANCE-M study was published in the Diabetes & Metabolism Journal (DMJ) and has demonstrated non-inferiority in the change rate of HbA1c compared to Dapagliflozin. It confirmed significant improvement of HOMA-IR, and showed excellent effects on improving albuminuria in the sub-analysis of diabetes patients with albuminuria. The ENHANCE-D study has been published in the international SCIE paper, ‘Diabetes & Metabolism (DM)’, and proved non-inferiority in the change rate of HbA1c compared to Dapagliflozin.

    “This research provides approval for a domestic new drug and meaningful clinical evidence to diabetes patients,” said Chang-jae Lee, representative of Daewoong Pharmaceutical. “Through this publication, we have verified excellent blood glucose lowering effects and metabolic improvements in Korean diabetes patients, and we are planning and conducting various studies to secure additional indications and clinical evidence for diabetes and other comorbidities such as heart disease, kidney disease, and obesity.”

    Logo – https://mma.prnewswire.com/media/1676530/Daewoong_Pharmaceuticals_Logo.jpg

    Cision View original content:https://www.prnewswire.co.uk/news-releases/daewoong-pharmaceutical-announce-publication-of-phase-3-study-of-envlo-a-new-treatment-for-diabetes-in-the-international-scie-journal-301805203.html

    Related Posts

    Booking Holdings Unveils Booking Partner Division to Accelerate B2B Travel Innovation

    November 18, 2026

    Emaar Partners with Huspy to Enhance Mortgage Advisory Services for Homebuyers

    November 18, 2026

    Ideas Abu Dhabi joins as an Official Partner to The Oasis at the 2026 UN Water Conference, Bringing Global Leaders and Breakthrough Innovations to the Main Stage

    November 18, 2026

    Experience Cinema-Quality Entertainment and Smarter Living with Hisense’s Best Year-End Offers

    November 18, 2026
    Latest Posts

    Petrol price jump lifts South Africa inflation as SARB weighs rates

    November 18, 2026

    Congo Ebola death toll reaches 5,568 as cases pass 11,000

    November 18, 2026

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026

    ASEAN signs digital economy pact eyeing $2 trillion by 2030

    November 18, 2026

    Tunisia tourism revenues top $2.38 billion by end-October

    November 17, 2026
    © 2026 Qatar Outlook | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.